← Back to ThePeptideMap
Weight Loss

Tirzepatide

A dual GIP/GLP-1 receptor agonist (Mounjaro/Zepbound) that outperformed semaglutide in trials, producing up to 22.5% average body weight loss — the highest of any approved drug to date.

Where to Get Tirzepatide

ℹ️ Affiliate disclosure: ThePeptideMap earns a commission when you visit a clinic or vendor through our links, at no extra cost to you.
ProviderTypePriceReviewLink
MYRNKTelehealth$129+/moRead reviewGet Started →
MadeMedTelehealth$199/moRead reviewGet Started →
Marek HealthTelehealth$166/moRead reviewGet Started →
Limitless Alt MedTelehealth$115–$275/moRead reviewGet Started →
NextGenPepsResearch$73 / 10mgVisit Site →

Telehealth = physician-prescribed. Research = for research use only, no prescription required. Learn the difference →

What Is Tirzepatide?

Tirzepatide is a novel dual agonist that simultaneously activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. Marketed as Mounjaro for diabetes and Zepbound for obesity, it represents the next generation of weight loss pharmacology — combining two complementary hormonal pathways to amplify satiety and metabolic benefits beyond what either agonist achieves alone.

Clinical Evidence

The SURMOUNT-1 trial (n=2,539) demonstrated 22.5% mean body weight loss at the highest dose (15mg/week) over 72 weeks — the largest weight reduction ever recorded in a phase 3 drug trial for obesity. In a direct head-to-head trial (SURMOUNT-5), tirzepatide produced 47% greater weight loss than semaglutide. Cardiometabolic benefits including blood pressure, triglycerides, and insulin resistance also showed superior improvement.

What to Expect

Tirzepatide users typically experience faster and more pronounced appetite suppression than semaglutide. The titration schedule starts at 2.5mg/week and advances every four weeks. Nausea is the most common early side effect and generally resolves after the first month. Compounded tirzepatide via telehealth offers cost savings of 60–80% versus brand-name Zepbound.

Typical Dose: 2.5mg/week (start) → up to 15mg/week
Form: Subcutaneous injection
Frequency: Once weekly
Protocol Length: 16–72+ weeks

Tirzepatide requires a physician prescription. Telehealth clinics offering compounded versions provide the most cost-effective access route. Research vendors (NextGenPeps) list it under the compound code GLP-TZ.